Humana · Letermovir · US health-plan appeal rights

Letermovir denied due to quantity / dose limits by Humana?

Q: How long do I have to appeal a Humana Letermovir denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for letermovir are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Letermovir (Prevymis) Prior Authorization for CMV Prophylaxis

The Humana angle on Letermovir

## Why Humana Applies Quantity Limits to Letermovir — and How to Appeal

Humana's quantity-limit edits for letermovir typically reflect the duration or supply parameters built into its specialty pharmacy benefit — often aligned with standard prophylaxis course lengths as defined in its coverage policy. A quantity-limit denial means Humana has approved some supply but will not authorize additional quantity beyond what its policy allows, either because the prescribed quantity per fill exceeds the plan's limit or because the total authorized duration has been reached. This denial is particularly consequential for transplant patients whose clinical course may require a longer prophylaxis period than the default policy allows.

## The Federal Legal Framework

ERISA §503: for employer-sponsored plans, Humana must provide a written denial specifying the quantity limit being applied and must afford a full-and-fair appeal.
ACA §2719: independent external review is available if the internal appeal is denied, generally within approximately four months of denial. Expedited review applies when the transplant patient's prophylaxis gap poses immediate clinical risk.

## Concrete Appeal Steps and Timeline

1. Request the specific quantity limit being applied: Humana must state whether this is a per-fill supply limit, a total duration cap, or a dose-frequency restriction. 2. First-level internal appeal: file within the deadline in the denial letter. Request expedited processing given transplant context; Humana must respond within 72 hours on an expedited basis. 3. Peer-to-peer review: the transplant prescriber should request a peer-to-peer call with Humana's medical director to explain why the patient's clinical situation requires a quantity or duration beyond the plan's standard limit. 4. External review: file for IRO review if internal appeals fail; quantity-limit denials grounded in a clinical need for extended prophylaxis are well-recognized IRO reversal scenarios.

## Documentation to Gather

Extended clinical need documentation: chart notes from the transplant team explaining the specific clinical reason the standard quantity or duration is insufficient — prolonged immunosuppression, high-risk CMV serostatus combination, slow immune reconstitution, or institutional protocol extending beyond plan defaults.
Transplant and CMV records: transplant type, date, donor/recipient CMV serostatus, and current immunosuppression regimen establishing why continued prophylaxis is medically necessary.
Prescriber letter: a letter from the transplant physician or transplant infectious disease specialist addressing Humana's quantity-limit criteria directly and documenting why the requested quantity is consistent with the standard of care for this patient's risk profile, referencing the relevant transplant guideline organization.
Humana's quantity-limit policy: obtain the current policy before writing the appeal so each criterion can be addressed.
Monitoring records: lab results and clinical notes showing ongoing risk factors that justify extended prophylaxis duration.

## Criteria-Mapping Structure

Build a two-column appeal table: left column, each element of Humana's quantity-limit criteria; right column, the specific chart finding that justifies the requested quantity or duration. The central argument is individualized medical necessity — that this patient's clinical profile, documented in the chart and supported by applicable transplant guidelines, requires more than the plan's default quantity allows. A prescriber peer-to-peer call plus a criteria-mapped appeal letter resolves the large majority of quantity-limit denials in this clinical category.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Letermovir

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.